RenuvoGen

RenuvoGen
Exclusive U.S. Distributor of the GCell Medical Device — A precision tissue-processing platform that mechanically cleanses and refines a patient's own tissue for same-session, point-of-care, cellular therapy treatments.



Our Mission
Precision Tissue Processing, Refined at the Point of Care
RenuvoGen is dedicated to bringing the most advanced, clinically validated autologous tissue processing solutions to medical professionals, clinic owners, and regenerative medicine specialists across the United States.
As the exclusive distributor of the GCell Medical Device, we empower providers to mechanically cleanse, refine, and concentrate a patient's own tissue — safely, efficiently, and in manner that aligns with FDA compliance guidelines— for same-session, point-of-care use without the need for a central processing laboratory.
Why RenuvoGen?
Exclusive U.S. distribution rights for the GCell platform
End-to-end clinical support and training
FDA registered device compliance
Proven tissue processing performance across orthopedics, aesthetics, and hair applications
Rapid, same-session tissue preparation for physician-directed use
The Device
Introducing the GCell Autologous Tissue Processing Device
The GCell is a FDA cleared, closed-system medical device engineered for same-session autologous tissue processing. Designed for point-of-care clinic use, it mechanically cleanses, refines, and concentrates a patient's own adipose or hair-derived tissue through slicing, mincing, filtration, washing, and centrifugation — all within a single, streamlined procedure. GCell uses no enzymatic digestion, no collagenase, no trypsin, and no chemical additives, preserving the tissue's native architecture throughout.
GCell Technology
How the GCell Processes Tissue

GCell does not extract or isolate stem cells as a standalone product. Instead, the platform mechanically processes a patient's own tissue through slicing, mincing, filtration, washing, and centrifugation — reducing blood, oils, fluid byproducts, and debris while preserving the tissue's native architecture. During this tissue separation process, the adipose-derived mesenchymal stem cells (AD-MSCs) naturally present in the tissue become concentrated, along with other resident progenitor cell populations, pericytes, stromal vascular fraction elements, extracellular matrix components, and signaling cytokines. 
This natural concentration of the tissue's own cellular and structural components — not a purified or cultured cell product — is what makes the resulting graft valuable for supporting the body's structural repair and healing processes. No enzymatic digestion, no cell culturing, no cell expansion, and no foreign chemical additives are used at any stage.
Therapy type 1
Adipose-Derived Mesenchymal Stem Cells (AD-MSCs)
Adipose-derived mesenchymal stem cells (AD-MSCs) are naturally occurring, multipotent progenitor cells present within a patient's own adipose tissue. During GCell's mechanical tissue processing — through washing, sizing, and centrifugation — these naturally resident AD-MSCs  along with stromal vascular fraction elements, endothelial progenitor cells, pericytes, macrophages, and regulatory T-cells, become concentrated within the resulting graft, along with other progenitor cell populations, extracellular matrix components, and signaling cytokines.
Naturally Occurring Properties
Naturally occurring immunomodulatory and anti-inflammatory signaling properties
Paracrine secretion of growth factors and cytokines — naturally present in adipose tissue
Capacity to support structural repair and the body's healing environment
100% autologous, patient-matched tissue
Therapy Type 2
Hair-Derived Tissue Processing for Physician-Directed Scalp Applications
Unipotent Progenitors
Naturally occurring, lineage-restricted progenitor cells found in the hair bulge and germ — concentrated during mechanical tissue processing without enzymatic digestion or cell expansion.
Keratinocytes
Naturally present structural cells of the hair shaft. Keratinocyte progenitors in the follicle bulge are preserved within the tissue graft during GCell's closed-loop mechanical processing.
Melanocyte Stem Cells
Naturally occurring pigment-producing progenitors present in hair-bearing tissue, concentrated within the refined graft during same-session tissue processing.
By mechanically processing biopsied hair-bearing tissue — without enzymatic digestion, cell culturing, or chemical additives — the GCell enables clinicians to prepare a refined autologous tissue graft for physician-directed scalp applications. This supports hair transplant procedures and scalp tissue handling using cells derived entirely from the patient's own follicular tissue, reintroduced during the same surgical session.
Clinical Applications
A Platform for Multiple Physician Specialties
Orthopedics & Sports Medicine
Physician-directed autologous tissue processing for orthopedic and sports medicine applications. The refined tissue graft supports structural cushioning, volume filling, and the body's healing environment in joint and soft tissue procedures.
Aesthetic & Anti-Aging Medicine
Autologous tissue processing for aesthetic medicine applications. The refined graft — rich in naturally occurring growth factors, ECM components, and signaling cytokines — supports structural volume filling and tissue handling as a natural alternative to synthetic fillers.
Hair Restoration & Transplantation
Mechanical, non-enzymatic processing of biopsied hair-bearing tissue for physician-directed scalp applications. Supports hair transplant procedures and scalp tissue handling using the patient's own follicular tissue, reintroduced in the same surgical session.
Regulatory & Safety Profile
Designed for Compliance. Built for Clinical Confidence.
Regulatory Status
The GCell is a FDA-registered medical device manufactured in compliance with international standards for autologous tissue processing. RenuvoGen supports U.S.-based clinics in navigating FDA guidelines for point-of-care, same-surgical-procedure autologous tissue use under the Section 361 HCT/P framework. As a closed, non-expanded, same-session mechanical processing system, the GCell is designed to satisfy FDA's minimal manipulation and homologous use standards under 21 CFR Part 1271.
Key Safety & Compliance Advantages
Closed System
No open processing — eliminates environmental contamination risk throughout the entire mechanical tissue processing workflow.
Autologous Only
100% patient-matched tissue — zero risk of immune rejection, disease transmission, or donor-matching complications. Tissue is removed and reintroduced into the same patient during the same procedure.
No Cell Expansion
Tissue is mechanically processed and reintroduced in the same session — no enzymatic digestion, no cell culturing, no cell expansion, and no foreign chemical additives. Fully compliant with the minimal manipulation standard.
Why Choose RenuvoGen
The Competitive Advantage of GCell at Your Clinic
Same-Session Treatment
Harvest, process, and reintroduce — all within a single patient visit. No lab wait times. No frozen samples. Same-day, point-of-care tissue preparation that maximizes clinical efficiency and patient experience.
FDA-Registered Device
Deploy with confidence. Designed to satify the FDAs guidelines for minimal manipulation, homologous, same session celluar therapy.The GCell meets clinical compliance across specialties.
Versatile Tissue Processing
One device. Two tissue sources — adipose and hair-bearing tissue — enabling multiple physician-directed applications and treatment protocols from a single platform.
Full Clinical Support
RenuvoGen provides comprehensive onboarding, protocol training, marketing materials, and ongoing clinical consultation for every practice partner — ensuring consistent, compliant use of the GCell platform.
For Clinic Owners & Investors
A High-Value Addition to Any Regenerative Practice
Revenue Opportunity
Expand service offerings across orthopedics, aesthetics, and hair applications with a compliant, physician-directed tissue processing platform
Command premium pricing for autologous, same-session tissue processing procedures
Differentiate your clinic with exclusive, CE-certified technology
Low per-procedure consumable cost relative to treatment fees
Operational Simplicity
Compact, tabletop device — no dedicated lab space required
Minimal staff training with RenuvoGen's structured onboarding program
Standardized protocol kits for consistent, reproducible tissue processing results
Dedicated account management and reorder support from RenuvoGen
Get Started
Partner with RenuvoGen
RenuvoGen is actively onboarding clinic partners, physician specialists, and investment partners across the United States. As the exclusive U.S. distributor of the GCell Medical Device, we offer a structured partnership model with full commercial and clinical support.
01
Request a Consultation
Speak with a RenuvoGen specialist to assess your practice needs and tissue processing application goals.
02
Device Demo & Protocol Review
Receive a virtual GCell demonstration and review compliant tissue processing protocols tailored to your specialty.
03
Onboard & Launch
Complete training, receive your device and starter kits, and begin offering physician-directed autologous tissue processing to your patients.


Contact RenuvoGen
Website: renuvogen.com
Email: [email protected]
Phone: 800-940-3060


Whether you are a physician, clinic owner, or investor evaluating the precision tissue processing market, RenuvoGen is your trusted partner for same-session, point-of-care autologous tissue preparation technology.